Rheoscience and Dr. Reddy's commence the first Phase III trial of Balaglitazone (DRF 2593)
Balaglitazone is a novel TZD candidate for the treatment of diabetes mellitus
03-Aug-2007 -
Rheoscience A/S and Dr. Reddy's Laboratories announced that the first patient has been dosed in a Phase III study with Balaglitazone (DRF2593-307), which is an insulin sensitizer that acts as a partial PPAR (peroxisome proliferator-activated receptor) gamma agonist. The study is the first in a ...
China
glucose
insulin
+5